Proteasome function and pathological proteins in the pathogenesis of Parkinson's disease

被引：3

作者：

Nomoto, M ^{[1
]}

Nagai, M ^{[1
]}

机构：

[1] Ehime Univ, Sch Med, Dept Clin Pharmacol & Therapeut, Tohon, Ehime 7910295, Japan

来源：

JOURNAL OF PHARMACOLOGICAL SCIENCES | 2005年 / 97卷 / 03期

关键词：

proteasome inhibitor; alpha-synuclein; Parkinson's disease; neurodegeneration;

D O I：

10.1254/jphs.LTJ05002X

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：455 / 456

页数：2

共 5 条

[1] How far are we in understanding the cause of Parkinson's disease? [J].

BenShlomo, Y .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (01) :4-16

[2] Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats [J].

Inden, M ;

Kondo, J ;

Kitamura, Y ;

Takata, K ;

Nishimura, K ;

Taniguchi, T ;

Sawada, H ;

Shimohama, S .

JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 (02) :203-211

[3] α-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines [J].

Martín-Clemente, B ;

Alvarez-Castelao, B ;

Mayo, I ;

Sierra, AB ;

Díaz, V ;

Milán, M ;

Fariñas, I ;

Gómez-Isla, T ;

Ferrer, I ;

Castaño, JG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (51) :52984-52990

[4] Proteasome inhibition causes nigral degeneration with inclusion bodies in rats [J].

McNaught, KS ;

Björklund, LM ;

Belizaire, R ;

Isacson, O ;

Jenner, P ;

Olanow, CW .

NEUROREPORT, 2002, 13 (11) :1437-1441

[5] Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease [J].

McNaught, KSP ;

Perl, DP ;

Brownell, AL ;

Olanow, CW .

ANNALS OF NEUROLOGY, 2004, 56 (01) :149-162

← 1 →